

Item 8.01 Other Events.

On November 7, 2018, the Center for Drug Evaluation of the National Medical Products Administration (f/k/a the China Food and Drug Administration) formally accepted the Investigative New Drug (IND) application for allogeneic adipose-derived mesenchymal progenitor cell (haMPC) off-the-shelf therapy AlloJoin® for Knee Osteoarthritis (KOA) submitted by Cellular Biomedicine Group Ltd. (Shanghai) and Wuxi Cellular Biopharmaceutical Group Ltd., each a wholly-owned subsidiary of Cellular Biomedicine Group, Inc. There can be no assurance that the application will ultimately be approved.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,
Inc.

Date: November 7, 2018 By: /s/ Bizuo (Tony) Liu
Bizuo (Tony) Liu
Chief Executive Officer